Cytori Therapeutics (NASDAQ:CYTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.
According to Zacks, “Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. “
CYTX has been the topic of several other research reports. B. Riley restated a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the company a “buy” rating in a research note on Monday, November 13th. Finally, ValuEngine upgraded shares of Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
In related news, major shareholder Ag Postfinance sold 236,155 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $0.34, for a total value of $80,292.70. Following the completion of the transaction, the insider now owns 5,311,451 shares of the company’s stock, valued at approximately $1,805,893.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Bank Sa Swissquote sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total transaction of $38,000.00. Following the completion of the transaction, the insider now directly owns 5,496,655 shares of the company’s stock, valued at approximately $2,088,728.90. The disclosure for this sale can be found here. Insiders have sold 408,785 shares of company stock valued at $142,987 over the last 90 days. 1.90% of the stock is currently owned by insiders.
Institutional investors have recently bought and sold shares of the stock. Perkins Capital Management Inc. boosted its stake in Cytori Therapeutics by 134.0% in the 4th quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock worth $644,000 after purchasing an additional 1,223,046 shares during the period. Vanguard Group Inc. boosted its stake in Cytori Therapeutics by 81.9% in the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock worth $674,000 after purchasing an additional 275,653 shares during the period. Finally, Sabby Management LLC boosted its stake in Cytori Therapeutics by 28.0% in the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock worth $1,789,000 after purchasing an additional 355,504 shares during the period. 10.82% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Cytori Therapeutics (CYTX) Lowered to “Sell” at Zacks Investment Research” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/13/cytori-therapeutics-cytx-lowered-to-sell-at-zacks-investment-research.html.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.